Low-dose bevacizumab as an effective pre-treatment for peri-tumoral brain edema prior to CyberKnife radiosurgery: A case report

References

• Lemercier P, Paz Maya S, Patrie JT, Flors L, Leiva-Salinas C. Gradient of apparent diffusion coefficient values in peritumoral edema helps in differentiation of glioblastoma from solitary metastatic lesions. AJR Am J Roentgenol. 2014;203:163–169. doi:10.2214/AJR.13.11186. PMID:24951211.
   PubMed Web of Science ®Google Scholar
• Palma L, Bruni G, Fiaschi AI, Mariottini A. Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon. A study on 21 patients. J Neurosurg Sci. 2006;50:63–66.
   PubMedGoogle Scholar
• Jeon YS, Koh YC, Song SW, Cho J, Lim SD. Palliative Resection of Metastatic Brain Tumors Previously Treated by Stereotactic Radiosurgery. Brain Tumor Res Treat. 2016;4:116–123. doi:10.14791/btrt.2016.4.2.116. PMID:27867922.
   PubMedGoogle Scholar
• Ly KI, Wen PY. Clinical Relevance of Steroid Use in Neuro-Oncology. Curr Neurol Neurosci Rep. 2017;17:5. doi:10.1007/s11910-017-0713-6. PMID:28138871.
   PubMed Web of Science ®Google Scholar
• Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. 2007;67:323–326. doi:10.1016/j.ijrobp.2006.10.010. PMID:17236958.
   PubMed Web of Science ®Google Scholar
• Pillay Smiley N, Alden T, Hartsell W, Fangusaro J. Severe Radiation Necrosis Successfully Treated With Bevacizumab in an Infant with Low-Grade Glioma and Tumor-Associated Intractable Trigeminal Neuralgia. Pediatr Blood Cancer. 2016;63:1671–1673. doi:10.1002/pbc.26055. PMID:27187113.
   PubMed Web of Science ®Google Scholar
• Furuse M, Nonoguchi N, Kawabata S, Miyata T, Toho T, Kuroiwa T, Miyatake S. Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas. Radiat Oncol. 2015;10:156. doi:10.1186/s13014-015-0446-0. PMID:26223253.
   PubMed Web of Science ®Google Scholar
• Sadraei NH, Dahiya S, Chao ST, Murphy ES, Osei-Boateng K, Xie H, Suh JH, Peereboom DM, Stevens GH, Ahluwalia MS. Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience. Am J Clin Oncol. 2015;38:304–310. doi:10.1097/COC.0b013e31829c3139. PMID:23799286.
   PubMed Web of Science ®Google Scholar
• Bitzer M, Opitz H, Popp J, Morgalla M, Gruber A, Heiss E, Voigt K. Angiogenesis and brain oedema in intracranial meningiomas: influence of vascular endothelial growth factor. Acta Neurochir (Wien). 1998;140:333–340. doi:10.1007/s007010050106. PMID:9689324.
   PubMed Web of Science ®Google Scholar
• Furuse M, Kawabata S, Kuroiwa T, Miyatake S. Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol. 2011;102:471–475. doi:10.1007/s11060-010-0333-3. PMID:20694573.
   PubMed Web of Science ®Google Scholar
• Benoit A, Ducray F, Cartalat-Carel S, Psimaras D, Ricard D, Honnorat J. Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis. J Neurol. 2011;258:328–329. doi:10.1007/s00415-010-5747-5. PMID:20862487.
   PubMed Web of Science ®Google Scholar
• Williams BJ, Park DM, Sheehan JP. Bevacizumab used for the treatment of severe, refractory perilesional edema due to an arteriovenous malformation treated with stereotactic radiosurgery. J Neurosurg. 2012;116:972–977. doi:10.3171/2012.1.JNS111627. PMID:22324417.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Sax C, Klein M, Furtner J, Dieckmann K, Gatterbauer B, Widhalm G, Rudas M, Zielinski CC, Bartsch R, et al. Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer: a case report. Breast Care (Basel). 2014;9:134–136. doi:10.1159/000360930. PMID:24944558.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang E, Pan L, Dai J, Zhang N, Wang X, Liu X, Mei G, Sheng X. A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema. J Neurooncol. 2014;119: 369–376. doi:10.1007/s11060-014-1488-0. PMID:24879376.
   PubMed Web of Science ®Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788–1795. doi:10.1038/sj.bjc.6603813. PMID:17519900.
   PubMed Web of Science ®Google Scholar
• Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis. 2002;5: 237–256. doi:10.1023/A:1024532022166. PMID:12906317.
   PubMedGoogle Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676. doi:10.1038/nm0603-669. PMID:12778165.
   PubMed Web of Science ®Google Scholar
• Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol. 2011;105: 281–289. doi:10.1007/s11060-011-0579-4. PMID:21603965.
   PubMed Web of Science ®Google Scholar
• Guinde J, Carron R, Tomasini P, Greillier L, Régis J, Barlesi F. Bevacizumab plus radiosurgery for non-squamous non-small cell lung cancer patients with brain metastases: a safe combination? World Neurosurg. 2017;107:1047.e1–1047.e4. doi:10.1016/j.wneu.2017.07.185. PMID:28803179.
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd, Eastern CooperativeOncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–1544. doi:10.1200/JCO.2006.09.6305. PMID:17442997.
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–2483. doi:10.1056/NEJMoa1104390. PMID:22204724.
   PubMed Web of Science ®Google Scholar